dallas skyline
Photo: Shutterstock

VC funding provided a boost to a wide variety of Dallas–Fort Worth companies in June. The top five funding rounds, which totaled a collective $198.3 million, helped accelerate the growth of companies in biotech, Web3 gaming and virtual wedding planning services, to name a few. Read on to find out which companies raised funds and how they plan to use their fresh capital.


#5. $1.3 million, June 15

Fêtefully is an online wedding planning service that helps couples build a budget, manage their guest list, pick a venue and navigate the world of wedding vendors. Last month’s $1.3 million funding round brought the company’s total funding raised to $2.6 million. Founder and CEO GiGi McDowell is one of 98 Black women founders to raise more than $1 million in venture funding.


#4. $14.5 million, June 2

Sanara MedTech raised $14.5 million, according to documents filed with the SEC on June 2. The Fort Worth-based company develops products and technologies that healthcare providers use for wound care and surgical tissue repair.


#3. $16.5 million, June 15

Nacuity Pharmaceuticals is a biopharmaceutical company developing treatments for eye diseases caused by oxidative stress, such as cataracts and retinitis pigmentosa. The company’s $16.5 million Series B round was led by Foundation Fighting Blindness and its venture arm RD Fund. The funding will be used to support the company’s upcoming clinical trials.


#2. $46 million, June 14

The Wildcard Alliance is a subsidiary of McKinney-based Playful Studios. The new subsidiary raised $46 million to launch a new Web3 gaming franchise called Wildcard, which is described in a news release as a hybrid of multiplayer online battle arena, real-time strategy and collectible card game where players compete surrounded by live, interactive fans and spectators. 


 #1. $120 million, June 29

ReCode Therapeutics, which is dual headquartered in Dallas and Menlo Park, California, added another $120 million to its $80 million Series B round from last year, bringing its total Series B funding to $200 million. ReCode, which has developed disease-modifying mRNA and gene correction therapeutics, is able to precisely target organs and cells beyond the liver with its selective-organ-targeting lipid nanoparticle platform. The company’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode was among the first DFW biotech companies to join Biotech+, a 40,000-square-foot co-working lab and office space that opened in March.

Great Companies Need Great People. That's Where We Come In.

Recruit With Us